

Practitioner's Docket No. MPI99-130P1RM

IN THE CLAIMS:

Please cancel claims 25-31, 37, 38, and 42-72 without prejudice or disclaimer and add new claims 73-85:

73. (New) A method of identifying whether a test compound is a candidate compound capable of modulating an MRR mediated bone-related disorder, the method comprising:
 - a. Combining a test compound with a composition comprising an MRR polypeptide, or a biologically active portion thereof;
 - b. Determining the ability of the test compound to bind with the MRR polypeptide, or biologically active portion thereof; and
 - c. Identifying the test compound as the candidate compound for use in modulating the MRR mediated bone-related disorder, when the test compound binds with the MRR polypeptide, or biologically active portion thereof.
74. (New) The method of claim 73 wherein the MRR mediated bone-related disorder is selected from the group consisting of osteoporosis, Paget's disease, osteomalacia, Cushing's syndrome, and osteogenic cancer.
75. (New) The method of claim 73 wherein the composition comprising an MRR polypeptide is selected from the group consisting of a cell expressing the MRR polypeptide, a membrane preparation comprising the MRR polypeptide, and an isolated MRR polypeptide.
76. (New) The method of claim 73 wherein the test compound is coupled with a detectable label.
77. (New) The method of claim 76 wherein the detectable label is a radioisotope.
78. (New) The method of claim 76 wherein the detectable label is an enzymatic label.